Table 3:

Participants with clinically important changes in outcomes, by follow-up time*

OutcomeNo. (%) of participantsp§
Treatment group (electroacupuncture with nocturnal splinting)
n = 90
Control group (nocturnal splinting only)
n = 91
BCTQ score
SSS
 Week 111 (12.2)19 (20.9)0.1
 Week 219 (21.1)23 (25.3)0.5
 Week 533 (37.9)27 (30.0)0.3
 Week 1740 (47.1)32 (36.0)0.1
FSS
 Week 17 (7.8)17 (18.7)0.03
 Week 215 (16.7)15 (16.5)1.0
 Week 519 (21.8)18 (20.0)0.8
 Week 1730 (35.3)21 (23.6)0.09
DASH score
Week 17 (7.8)16 (17.6)0.05
Week 217 (18.9)19 (20.9)0.7
Week 524 (27.6)21 (23.3)0.5
Week 1740 (47.1)26 (29.2)0.02
Pain intensity
Week 118 (20.0)20 (22.0)0.7
Week 221 (23.3)24 (26.4)0.6
Week 527 (31.0)28 (31.1)1.0
Week 1734 (40.0)31 (34.8)0.5
Blinded DMMPUT completion time
Week 1732 (37.6)17 (19.1)< 0.01
Tip pinch strength
Week 1739 (45.9)32 (36.0)0.2
  • Note: BCTQ = Boston Carpal Tunnel Questionnaire, DASH = Disability of Hand and Shoulder Questionnaire, DMMPUT = Dellon-modified Moberg pick-up test, FSS = Functional Status Scale.

  • * Threshold for a minimally important difference is defined as a half of the baseline SD for SSS, FSS, DASH and DMMPUT, 1.66 lb for tip pinch strength, and 2 for pain intensity measured on a numerical rating scale.

  • Particpants left trial (n = 87 for the treatment group, n = 90 for the control group).

  • Particpants left trial (n = 85 for the treatment group, n = 89 for the control group).

  • § Two-sided p values for comparing proportions of patients showing clinically important changes between groups.